Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $57.33, along with a high estimate of $62.00 and a low estimate of $50.00. Marking an ...

Vertex Pharmaceuticals (Nasdaq: VRTX) and Ono Pharmaceutical (OTCMKTS: OPHLY) have announced an exclusive collaboration, for the development and commercialization of Vertex's povetacicept in Japan ...

Vertex (VERX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Vertex (VERX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vertex is consistently recognized as one of the industry's top places to work, including being named to Science magazine's Top Employers in the life sciences ranking for nine years in a row.